Private Label OTC Giant Stretches For Switch Help
Perrigo Will Pay $2.1Bn In Cash Deal For HRA Pharma
Executive Summary
HRA brings needed expertise in OTC switches to Perrigo, which regularly is first to launch generic equivalents for brand switches but its name hasn’t been linked to submitting proposals for making additional drug ingredients available OTC.
You may also be interested in...
HRA Brings Mederma Scar-Care Brand To UK
British consumers can now buy three Mederma scar-care products in the UK via Amazon and Superdrug thanks to a recent launch by France's HRA Pharma.
Preparing For Expansion: Perrigo Sets $500M Private Offering, Bausch + Lomb IPO Details Filed
Perrigo intends to use net proceeds from $500m private offering along with cash on hand and funds from previous credit facilities to finance acquisition of HRA Pharma. Bausch Health reduces debt by $200m as it prepares to target proceeds from planned Bausch + Lomb IPO also to paying down debt.
Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions
“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.